Roche signs drug licensing agreement with MPP

05-08-2013

Roche signs drug licensing agreement with MPP

On August 5, Swiss pharmaceutical company Roche signed an agreement with the Medicines Patent Pool (MPP) to increase access to its drug valganciclovir (Valcyte), an oral medicine for the treatment of preventable viral infection cytomegalovirus (CMV).


Roche, MPP, CMV, HIV, Valcyte

LSIPR